MB. CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway. Am
IN THE UNITED STATES, end-stage liver disease is the fifth leading cause of death among people during their most productive phase of life [45-to 64-yr-old age group (National Vital Statistics Report 2011)]. In these patients, complications associated with portal hypertension, including ascites, hepatic encephalopathy, and hemorrhage from gastroesophageal varices are the main causes of death (5) . In the normal liver, hepatic stellate cells (HSCs) are quiescent, vitamin A-rich cells located between sinusoidal endothelial cells and hepatocytes in the space of Disse (9) . During injury, these quiescent cells differentiate into highly proliferative and contractile fibrogenic cells that increase expression of contractile proteins including ␣-smooth muscle actin (␣-SMA). HSCs additionally resemble tissue pericytes, a cell population that has smooth muscle features and is thought to regulate blood flow by modulating pericapillary resistance (22) . They contract to factors such as endothelin-1 (ET-1) and angiotensin, which are elevated during liver injury implicating stellate cell contraction in the pathogenesis of portal hypertension (3, 14) . In all etiologies of liver disease, hepatic expression of CXCR4 and both serum and hepatic levels of CXCL12 are increased (12, 25) . In the liver, CXCL12 is expressed by bile duct epithelia, sinusoidal endothelial cells, and HSCs; however, the function of this chemokine in liver disease is not well understood (12, 20, 25) . We have previously reported that activated HSCs express functional CXCR4 and that receptor engagement by its ligand, CXCL12, leads to a profibrogenic phenotype characterized by increased proliferative capacity and collagen type I and ␣-SMA production (12) . Furthermore, others have shown that CXCL12 promotes HSC migration and chemotaxis (20) . Here we show that CXCL12 induces cellular contraction and myosin light chain phosphorylation in a CXCR4 and Rho kinasedependent manner.
MATERIALS AND METHODS

Cell lines.
All experiments were performed with JS1 cells unless otherwise noted. JS1 cells are a murine SV40 immortalized HSC line with a highly activated phenotype (11) . For other experiments (where stated), the LX2 spontaneously immortalized human stellate cell line was used (10) .
Isolation of primary human HSCs. Primary stellate cells were isolated from wedge sections of normal human liver in patients undergoing hepatic resection for primary benign tumors or single metastasis from colon cancer as previously described (12) . These studies have been approved by the Mount Sinai IRB and designated exempt category 4 (GCO no. 06-0523). Briefly, immediately after hepatectomy, the liver was placed in DMEM. The liver was washed and portal venules cannulated for in situ digestion with pronase (Roche Applied Sciences, Mannheim, Germany) and collagenase B (Roche Applied Sciences). Stellate cells were isolated via density centrifugation and plated on plastic in DMEM supplemented with 10% FBS. HSCs were activated by culturing on plastic for 7-12 days and subcultured to passage 3 for all experiments.
Collagen gel contraction assay. The ability of HSCs to contract in response to CXCL12 was evaluated by using collagen gel lattices in 24-well culture plates as previously described (19) . The 24-well plates were incubated with 1% sterile BSA in PBS for 1 h at 37°C, washed twice with PBS, and air dried. Eight parts type 1 bovine collagen, PureCol (Advanced BioMatrix, San Diego, CA), were added to 1 part 10ϫ MEM (GIBCO, Grand Island, NY) and 1 part 0.2 M HEPES (resulting in a final collagen concentration of 2.4 mg/ml), pH adjusted to 7.4, and 500 l added to each well. Collagen gels were allowed to solidify at 37°C for 1 h. After gelation, 1 ϫ 10 5 JS1, LX2 or primary human stellate cells in 1 ml 10% FBS-1% P/S DMEM media were added on top of the gels and incubated for 24 h. Cells were serum starved in 0.2% BSA DMEM overnight. Gels were detached from the plates and treated for 24 h with species-specific recombinant CXCL12 (R&D Systems, Minneapolis, MN) or synthetic human ET-1 (Sigma, St. Louis, MO). For Rho kinase or CXCR4 inhibition, serum-free medium containing 25 M Y-27632 (EMD Chemicals) or 5 g/ml AMD3100 (Sigma), respectively, was added to the cells for 30 min prior to adding CXCL12. For analysis, gels were scanned and area was measured by use of digital image analysis software. All experiments were performed in triplicate.
Immunoblots. Expression of ␣-SMA and phosphorylated myosin light chain 2 (pMLC-2) was examined in JS1 and LX2 cells. Briefly, 10 5 JS1, LX2, or primary human stellate cells were plated in six-well plates and after 24 h serum starved overnight in 0.2% BSA DMEM. Cells were stimulated with species-appropriate recombinant CXCL12 (0 -750 ng/ml), for 1-24 h. Cells were further treated with 25 ng/ml murine recombinant CCL5 (R&D Systems), which is the optimal concentration to promote stellate cell migration and proliferation (21) collected for 24 -96 h, centrifuged to remove particulate debris, and frozen at Ϫ80°C until time of assay. Samples were prepared and assays were performed according to manufacturer's protocol (DSA00, R&D Systems, Minneapolis, MN). Medium incubated without cells was used as a negative control. Standard curves were generated by use of purified recombinant murine CXCL12. FACS analysis for cell surface and total CXCR4. FACS analysis was performed to demonstrate both cell surface and total CXCR4 expression by JS1 cells. For cell surface expression, cells were collected by vigorous pipetting in PBS. Nonspecific binding was blocked by incubating cells in 1:200 dilution mouse serum (Sigma) for 30 min followed by addition of 1:100 rat anti-mouse monoclonal CXCR4 conjugated to APC (BD Pharmingen, Clone 2B11) or Rat IgG2b isotype control conjugated to APC (BD Pharmingen) for 1 h. Cells were washed in FACS buffer and samples analyzed on a BD LSRII (BD Biosciences). For total CXCR4 expression, JS1 cells were fixed and permeabilized with IC fixation and permeabilization buffer (eBiosciences) followed by blocking and incubation with CXCR4-APC or RatIgG2b-APC for 1 h. For TGF-␤ 1 stimulation, cells were treated with hTGF-␤1 for 2 h prior to collection and staining.
Immunostaining for CXCR4. For the detection of CXCR4 on stellate cells by immunostaining, JS1 cells were grown in chamber slides, fixed in 4% PFA for 10 min, permeabilized with 0.5% Triton/ PBS for 20 min at 37°C, and blocked for 1 h with blocking solution (PBS with 1% bovine serum albumin, 0.1% Triton). Subsequently, cells were incubated with rabbit anti-mouse polyclonal CXCR4 at 1:100 dilation (eBiosciences) or isotype control. Slides were washed in PBS and incubated for 30 min at room temperature with goat anti-rabbit AlexaFluor 488 (Molecular Probes, Grand Island, NY) at a dilution of 1:200. The cells were mounted with ProLong Gold mounting media containing DAPI (Molecular Probes). Images were acquired with a Zeiss Axiophot 2 fluorescence microscope (Zeiss, Oberkochen, Germany).
Calcium influx assay. Changes in cytosolic calcium were determined with confocal video microscopy performed with live human LX2 or murine JS1 stellate cells grown on glass coverslips. Cells were loaded with the calcium-sensitive fluorophore Fluo-4 AM (Molecular Probes) for 20 min at 37°C and mounted on a specially designed stage for use on a confocal microscope, prior to recording. Cells were perfused with HEPES buffer, followed by treatment with HEPES buffer containing CXCL12 (750 250 ng/ml) or ATP (100 M). Changes in Fluo-4 fluorescence were monitored by use of a Zeiss LSM 510 (Zeiss, Thornwood, NY) confocal imaging system. Fluo-4 fluorescence was excited with a krypton-argon laser at 488 nm; emitted fluorescence at Ͼ515 nm was collected. Changes in fluorescence over time were expressed as peak fluorescence divided by or subtracted to initial fluorescence.
Knockdown of CXCR4 and ROCK1 in JS1 cells. JS1 cells were grown to 80% confluence and transfected with HuSH shRNA for CXCR4 (cat. no. TR30007, Origene, Rockville, MD) or SureSilencing shRNA for ROCK1 (cat. no. KM04660G, SABiosciences, Valencia, CA). After 24 h, cells were trypsinized and 10 5 cells subcultured into six-well plates. Cells were allowed to grow for 24 h, serum starved overnight, and treated as mentioned above and knockdown confirmed by Western blot analysis.
Measurement of cell viability. Cell viability was measured with the MTT Cell Growth Assay Kit (Millipore). We seeded 3 ϫ 10 3 JS1 cells in a 96-well plated for 24 h. Cells were serum starved overnight and treated with 25 M Y-27632 for 2.5 h, and cell viability was measured according to manufacturer's protocol.
Statistics. All results are expressed as means Ϯ SD. Statistical significance was tested by an unpaired Student's t-test, and P Ͻ 0.05 indicated a significant difference.
RESULTS
JS1 cells, a murine HSC line, express CXCR4 and CXCL12.
We have previously reported that activated human HSCs express both the CXCR4 receptor and its ligand, CXCL12 (12) . To determine whether JS1 cells express CXCR4, we performed FACS analysis for both total and cell surface expression and immunofluorescent staining (Fig. 1, A and B) . FACS analysis demonstrates that 100% of JS1 cells express CXCR4 while 21% express it on their cell surface. This is similar to neutrophils, dendritic cells, and macrophages, which contain intracellular cytoplasmic endosomes of CXCR4 that are able localize to the cell surface upon stimulation (4, 7, 18, 26) . To determine whether JS1 cells express the CXCR4 ligand, CXCL12, we performed ELISA on cell culture supernatant from JS1 cells collected between 0 and 96 h (Fig. 1C) . There is a time-dependent increase in the secretion and accumulation of CXCL12 and by 96 h the concentration was over 6,000 pg/ml. CXCL12 leads to upregulation of ␣-SMA, phosphorylation of MLC, and HSC contraction. Because CXCL12 promotes an activated phenotype in HSCs, we tested whether stimulation with exogenous recombinant CXCL12 leads to increased expression of ␣-SMA, a critical protein in contraction. JS1 cells were treated with increasing concentrations of recombinant murine CXCL12 for 24 h and Western blot analysis performed for ␣-SMA (Fig. 2A) . Maximum expression of ␣-SMA was seen with a dose of 250 ng/ml CXCL12; therefore, this dosage was chosen for all other experiments. The mechanism of cellular contraction is well described, and the final step requires the phosphorylation of myosin light chain 2 (MLC-2) and we show that CXCL12 leads to an increase in the phosphorylation of MLC-2. JS1 cells were treated with 250 ng/ml of CXCL12 for 0 -8 h and Western blot analysis performed with an antibody that recognizes the phosphorylated form of MLC-2 (Fig. 2B) . At 2 h after treatment we saw the greatest increase in MLC-2 phosphorylation. To determine that CXCL12 can also lead to stellate cell contraction we treated JS1 cells plated on collagen lattices with 250 ng/ml CXCL12 for 24 h. Treatment of collagen gels with CXCL12 1; B) show a time-dependent increase in phosphorylation of MLC-2. LX2 cells seeded on collagen gels and treated with 750 ng/ml CXCL12 for 24 h shows gel contraction (C) (representative image). SFM, serum-free medium. Quantification of LX2 collagen gel contraction in response to CXCL12 and ET-1 (D). Similarly, primary human stellate cells treated with 750 ng/ml human CXCL12 or 2 ϫ 10 Ϫ8 M ET-1 show an increase in MLC-2 phosphorylation (E) and collagen gel contraction (F and G). *P Ͻ 0.05, **P Ͻ 0.005, ***P Ͻ 0.001; n ϭ 6 from 3 independent experiments. led to a 21% decrease in collagen gel area (Fig. 2, C and D) . Interestingly, even without addition of exogenous CXCL12 there was significant MLC-2 phosphorylation and a 13% contraction of collagen gels. As HSCs express both CXCR4 and its ligand CXCL12, they form a potential autocrine loop capable of inducing contraction and therefore exhibit a high level of basal contraction. Finally, to show that stellate cell contraction is not a general chemokine phenomenon, but specific to CXCL12, we show that there is no increase in MLC-2 phosphorylation after treatment with 25 ng/ml CCL5 (Fig. 2E) .
CXCL12 leads to MLC phosphorylation and HSC contraction in human HSCs. To show that CXCL12 also induces contraction in human HSCs we used the LX2 cell line, a human immortalized stellate cell line and primary human HSCs (hHSCs). We have previously shown that both LX2 cells and hHSCs express CXCR4 and CXCL12 and stimulation with exogenous human CXCL12 leads to an increase in ␣-SMA (12) . Stimulation of LX2 cells with CXCL12 or ET-1, a well-established contractile factor, led to an increase in pMLC-2 and contraction in LX2 cells in a time-dependent manner (Fig. 3, A and B) . Treatment of LX2 cells on collagen gels with increasing concentrations of CXCL12 showed that maximal contraction occurs at 750 ng/ml CXCL12 and that CXCL12 leads to a slightly greater overall contractile response than 2 ϫ 10 Ϫ8 M ET-1 (Fig. 3, C and D) . Similarly, we show that, in primary human HSCs, stimulation with CXCL12 promotes both MLC-2 phosphorylation (Fig. 3E ) and collagen gel contraction (Fig. 3, F and G) . However, unlike LX2 cells, hHSCs are more responsive to ET-1 than CXCL12.
CXCL12-induced contraction signals through CXCR4.
To determine that CXCL12 induced contraction occurs through the CXCR4 receptor, we pretreated JS1 cells with the CXCR4 small molecule inhibitor AMD3100 or knocked down CXCR4 using shRNA. Prior to addition of CXCL12, JS1 cells were treated with 5 g/ml AMD3100 for 30 min. For CXCR4 knockdown experiments, JS1 cells were transfected with either scrambled shRNA (shSCR) or CXCR4-targeted shRNA (shCXCR4). Treatment of JS1 cells with 250 ng/ml CXCL12 after CXCR4 inhibition failed to induce MLC phosphorylation (Fig. 4, A and B) . Additionally, pretreatment with AMD3100 prevented JS1 cells from contracting over baseline in response to CXCL12 (Fig. 4, C and D) . The reduction in pMLC-2 and collagen gel contraction after CXCR4 inhibition indicates that the effect is mediated through CXCR4.
As previously mentioned, JS1 cells secrete high levels of CXCL12 and express functional CXCR4 establishing a potential autocrine loop as can be seen by basal level MLC-2 phosphorylation and collagen gel contraction (Fig. 2, B and D) . Here we demonstrate that this autocrine loop is responsible for basal MLC-2 phosphorylation as CXCR4 inhibition with AMD3100 or CXCR4 knockdown with shCXCR4 in the absence of exogenous CXCL12 decreases the extent of MLC-2 phosphorylation (compare lanes 1 and 4 in Fig. 4, A and B) .
HSC contraction is not calcium dependent. CXCL12 is known to stimulate calcium flux in many cell types (1, 8) . To demonstrate CXCL12-mediated calcium influx in HSCs we treated both human and murine stellate cells loaded with Fluo-4 calcium sensitive dye with CXCL12 at the concentration that promotes maximal ␣-SMA expression and measured the relative increase in fluorescence using confocal microscopy. In human LX2 cells treatment with CXCL12 led to a nearly twofold increase in relative fluorescence (Fig. 5, A and B) whereas in murine JS1 cells CXCL12 did not promote calcium transience (Fig. 5C ). Despite the effect of CXCL12 on calcium flux in human LX2 cells, pretreatment of either LX2 (Fig. 5D) or JS1 (Fig. 5E ) cells with 50 M BAPTA-AM, an intracellular calcium chelator, did not affect the extent of CXCL12 mediated MLC phosphorylation, indicating that the mechanism of action is not calcium dependent.
CXCL12-dependent contraction is mediated through the Rho kinase pathway. To demonstrate that CXCL12-dependent contraction signals through Rho kinase, we used shRNA to knock down ROCK1 (Rho-associated protein kinase 1), a Rho kinase isoform shown to be important in MLC phosphorylation (16) . JS1 cells were transfected with either shSCR or ROCK1-targeted shRNA. Western blot analysis shows that treatment of JS1 cells with 250 ng/ml CXCL12 after ROCK1 knockdown fails to induce MLC phosphorylation (Fig. 6A) . Additionally, we show that pretreatment with the Rho kinase inhibitor Y-27632 for 30 min followed by stimulation with 250 ng/ml CXCL12 fully abrogated CXCL12-induced MLC phosphorylation (Fig. 6B ) and that treatment of JS1 cells on collagen lattices with Y-27632 also abolished gel contraction (Fig. 6 , C and D) whereas Y-27632 treatment did not affect cell viability as measured by MTT assay (Fig. 6E) .
DISCUSSION
In this study we show that HSCs contract in response CXCL12 through CXCR4 in a Rho kinase-dependent mechanism. We have previously reported that CXCL12 leads to an increased fibrogenic phenotype and now show an additional role for CXCL12 in stellate cell biology. Quiescent stellate cells do not express cell surface CXCR4; however, with activation during liver injury stellate cells begin to express CXCR4 and acquire a profibrogenic profile. In the normal liver CXCL12, the CXCR4 ligand, is predominantly expressed by biliary epithelial cells (BECs) (25) . During progressive injury there is an anatomical and cellular redistribution of CXCL12 to proliferating bile ducts and to cells of the fibrotic septae including sinusoidal endothelial cells and HSCs (12) . We show that stellate cells express functional cell surface and intracellular CXCR4 and secrete high levels of CXCL12, allowing for both paracrine (from BECs and liver sinusoidal endothelial cells) and autocrine stimulation. Activation of both human and murine stellate cells with exogenous CXCL12 led to phosphorylation of MLC-2 and stellate cell contraction to a similar extent of ET-1. The dose of CXCL12 required for maximal contraction in LX2 cells and hHSCs is greater than that of JS1 cells, 750 ng/ml vs. 250 ng/ml, respectively, and may be due to the levels of endogenous CXCL12 secreted by primary human stellate and LX2 cells. We have previously shown that LX2 cells and hHSCs cells secrete ϳ3,000 pg/ml CXCL12 vs. 6,000 pg/ml in JS1 cells (12) . This difference may also be responsible for the lower level of basal contraction seen in the human cells since we show that endogenously secreted CXCL12 is responsible for basal MLC-2 phosphorylation as inhibiting CXCR4 decreases pMLC-2 even in the absence of CXCL12 stimulation.
The final step in the induction of cell contraction is phosphorylation of MLC-2. Two mechanistically distinct pathways exist: the calcium-dependent pathway and the calcium-sensitive pathway. In the calcium-dependent pathway, primarily found in skeletal and cardiac muscle, release of calcium from the endoplasmic/sarcoplasmic reticulum leads to activation of MLC kinase by calmodulin and subsequent phosphorylation of MLC. Alternatively, in the calcium-sensitive pathway, active in smooth muscle-like cells, Rho kinase phosphorylates the myosin binding subunit, thereby inactivating it and preventing it from dephosphorylating MLC and inhibiting contraction. The net effect of Rho kinase activation is increased phosphorylated MLC and contraction. CXCL12 is well known to induce calcium transience in numerous cell types which is important in cellular chemotaxis and migration (2, 15) . We show that CXCL12 induces calcium transience in LX2 but not JS1 cells at the CXCL12 concentrations that promoted maximum ␣-SMA expression in each cell type. Despite this difference, in both LX2 and JS1 cells, preincubation of cells with a calcium chelator did not inhibit CXCL12 induced contraction, indicating that this pathway is not calcium-dependent but signals through the Rho kinasemediated calcium-sensitive pathway.
The role of Rho kinases in liver disease has been studied extensively and is implicated in activation and contraction of stellate cells. We demonstrate that CXCL12 signals by activating the Rho kinase pathway as stellate cell stimulation with CXCL12 after knockdown of Rho kinase isoform ROCK1 failed to induce MLC-2 phosphorylation. Finally, systemic and stellate cell-specific delivery of Y-27632, a Rho kinase inhibitor, leads to decreased fibrosis in murine models of liver injury (13, 23, 24) . Similar to previous reports that HSC contraction occurs through the Rho kinase pathway, we show that pretreatment of stellate cells with Y-27632 abolishes CXCL12-induced contraction.
Despite the identification of vasoactive factors contributing to increased sinusoidal resistance, treatment options for these patients remain limited since inhibiting these pathways leads to systemic vascular effects with minimal hepatic response. The CXCL12/CXCR4 axis is not involved in normal homeostatic vasoregulation, and in healthy tissue vascular smooth muscle cells and pericytes do not express CXCR4. Only during injury do vascular smooth muscle cells begin to express CXCR4 (6) . Additionally, in models of cardiac infarction, coronary microvessels specifically from injured tissue, but not healthy controls, contract in response to CXCL12 (17) . Blocking the CXCL12/CXCR4 axis in patients with portal hypertension would therefore potentially have liver-specific effects. We show that blocking CXCR4 with AMD3100, which is FDA approved for treatment of multiple myeloma, leads to a decrease in contraction and phosphorylation of MLC-2 in stellate cells and may be useful in mitigating both paracrine and autocrine CXCL12-induced contraction. Blocking this axis therefore may prove beneficial in long-term management of portal hypertension by preventing or retarding the development of life-threatening varices. These studies form the basis for testing this axis in rodent models of portal hypertension.
In conclusion, our data provide the first evidence of CXCR4-dependent stellate cell contraction. The specificity of CXCR4 vasoregulation to injured tissue and the commercial availability of orally bioavailable small molecule inhibitors specific for CXCR4 justify further investigation into its role as a therapeutic target.
